XML 216 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:    
Net loss $ (19,985,000) $ (20,840,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation expense 1,653,000 2,038,000
Depreciation and amortization 174,000 189,000
Loss from equity method investment 130,000 0
Loss on disposal of fixed assets 0 3,000
Amortization/accretion on marketable securities (455,000) (960,000)
Changes in operating assets and liabilities:    
Accounts receivable (900,000) 0
Prepaid and other current assets 852,000 (824,000)
Other assets 170,000 274,000
Accounts payable, accrued liabilities and other liabilities (995,000) 88,000
Net cash used in operating activities (19,356,000) (20,032,000)
Cash flows from investing activities:    
Purchase of marketable securities (55,688,000) (98,479,000)
Sales of marketable securities 69,051,000 108,581,000
Investment in Impilo Therapeutics (130,000) 0
Net cash provided by investing activities 13,233,000 10,102,000
Cash flows from financing activities:    
Proceeds from exercise of options 0 155,000
Tax withholding payments on net share settlement equity awards (274,000) (91,000)
Net proceeds from issuance of common stock 68,000 321,000
Net cash (used in) provided by financing activities (206,000) 385,000
Effect of exchange rate changes on cash (55,000) (16,000)
Net decrease in cash and cash equivalents (6,384,000) (9,561,000)
Cash and cash equivalents at beginning of year 22,593,000 32,154,000
Cash and cash equivalents at end of year $ 16,209,000 $ 22,593,000